1. Home
  2. Search Results

Search Results

All
Leukaemia
Category: Research
Leukaemia is a cancer of the blood or bone marrow involving abnormal ... – Australian Institute of Health and Welfare ) Acute Lymphoblastic Leukaemia (ALL) is one of the most deadly and most common ... with leukaemia. Another type of leukaemia, Acute myeloid leukaemia (AML), is a rapidly progressing blood cancer predominantly ...
Defining the role of shwachman-bodien diamond syndrome protein (SBDS) in PP2A inhibition in acute myeloid leukaemia (AML)
Category: Research
A new treatment for acute myeloid leukaemia Acute myeloid leukaemia (AML) is the most common and deadly ...
Improving the effectiveness of a new treatment for acute myeloid leukaemia (AML)
Category: Research
Acute myeloid leukaemia (AML) is the most common acute leukaemia affecting adults, and accounts for ~20% ...
Targeting BAALC as a new treatment for acute myeloid leukaemia
Category: Research
Improving survival from Acute myeloid leukaemia (AML) with new therapies Acute myeloid leukaemia (AML) is the ...
Identifying novel therapeutic targets for the treatment of Acute Myeloid Leukaemia
Category: Research
... Finding the ‘disease-causing’ mutations and proteins in Acute Myeloid Leukaemia to develop new treatment strategies. Acute Myeloid Leukaemia ...
Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS
Category: Research
AML (acute myeloid leukemia) is a very aggressive form of leukemia. Tumour ... Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS ...
Developing new treatments for resistance in acute myeloid leukaemia
Category: Research
... for the most common and deadly form of blood cancer (acute myeloid leukaemia) hasn’t changed in over 40 years. New treatments fail because ...
Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS
Category: Research
AML (acute myeloid leukemia) is a very aggressive form of leukemia. Tumour ... Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS ...
Developing new treatments for resistance in acute myeloid leukaemia
Category: Research
... for the most common and deadly form of blood cancer (acute myeloid leukaemia) hasn’t changed in over 40 years. New treatments fail because ...
Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS
Category: Research
AML (acute myeloid leukemia) is a very aggressive form of leukemia. Tumour ... Receptor tyrosine kinase mutations in acute myeloid leukaemia promote PP2A and p53 inhibition through the phosphorylation of SBDS ...